Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) Net Margin: 2014-2025

Historic Net Margin for CytomX Therapeutics (CTMX) over the last 11 years, with Sep 2025 value amounting to -238.62%.

  • CytomX Therapeutics' Net Margin fell 25578.00% to -238.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 24.66%, marking a year-over-year increase of 1373.00%. This contributed to the annual value of 23.08% for FY2024, which is 2364.00% up from last year.
  • As of Q3 2025, CytomX Therapeutics' Net Margin stood at -238.62%, which was down 28,810.39% from -0.83% recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' Net Margin registered a high of 49.55% during Q4 2024, and its lowest value of -353.77% during Q1 2022.
  • Its 3-year average for Net Margin is -11.21%, with a median of 3.15% in 2023.
  • As far as peak fluctuations go, CytomX Therapeutics' Net Margin plummeted by 32,033bps in 2021, and later skyrocketed by 33,968bps in 2023.
  • Over the past 5 years, CytomX Therapeutics' Net Margin (Quarterly) stood at -312.82% in 2021, then surged by 26,921bps to -43.61% in 2022, then soared by 4,675bps to 3.15% in 2023, then skyrocketed by 4,641bps to 49.55% in 2024, then crashed by 25,578bps to -238.62% in 2025.
  • Its Net Margin stands at -238.62% for Q3 2025, versus -0.83% for Q2 2025 and 46.20% for Q1 2025.